BioAtla announced presentation of mecbotamab vedotin clinical data at SITC 2025, highlighting its efficacy in treating specific sarcomas.
Quiver AI Summary
BioAtla, Inc., a clinical-stage biotechnology company focused on antibody therapeutics for solid tumors, has announced that it will present clinical data for its AXL-targeting antibody-drug conjugate, mecbotamab vedotin (BA3011), at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting in November 2025. The presentation will share findings on the median overall survival of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with the drug. Dr. Mihaela Druta from Moffitt Cancer Center will deliver the presentation on November 7, 2025, with the relevant materials available on BioAtla's website post-presentation. BioAtla is headquartered in San Diego and has a significant portfolio of patents related to its proprietary Conditionally Active Biologic platform.
Potential Positives
- Presentation of clinical data at a notable industry event (SITC 2025 Annual Meeting) highlights the company's innovative research efforts in solid tumors.
- Encouraging median overall survival (OS) results of 21.5 months in treatment-refractory patients demonstrate the potential effectiveness of mecbotamab vedotin.
- Broad patent coverage with over 780 active patent matters provides a strong intellectual property position that can enhance market competitiveness.
- The proprietary CAB platform technology may lead to the development of more selective and effective therapies, positioning BioAtla favorably in the biotechnology sector.
Potential Negatives
- The presentation is highlighted to focus primarily on only 44 patients, which could raise concerns about the robustness and generalizability of the clinical data.
- The mention of "treatment-refractory" conditions may imply that the investigational treatment has limited effectiveness in the general patient population, which could deter investor interest.
- While presenting at a major conference is positive, it may indicate that the company is still in the early stages of development for its products, suggesting a longer timeline before potential commercialization.
FAQ
What is mecbotamab vedotin?
Mecbotamab vedotin is an investigational AXL-targeting antibody-drug conjugate developed by BioAtla for treating solid tumors.
When will the clinical data for mecbotamab vedotin be presented?
The clinical data will be presented at the SITC 2025 Annual Meeting from November 5-9, 2025.
Who is presenting the data on mecbotamab vedotin?
Dr. Mihaela Druta from Moffitt Cancer Center will present the data on November 7, 2025.
Where can I access the presentation materials for the mecbotamab vedotin results?
Presentation materials will be available in the “Publication” section on BioAtla’s website after the presentation concludes.
What are the benefits of BioAtla's CAB platform technology?
BioAtla's CAB platform offers selective targeting, greater efficacy, reduced toxicity, and cost-efficient manufacturing compared to traditional antibodies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BCAB Hedge Fund Activity
We have seen 13 institutional investors add shares of $BCAB stock to their portfolio, and 21 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ACORN CAPITAL ADVISORS, LLC added 803,065 shares (+19.9%) to their portfolio in Q2 2025, for an estimated $318,013
- NORGES BANK removed 389,100 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $154,083
- MORGAN STANLEY removed 280,016 shares (-47.0%) from their portfolio in Q2 2025, for an estimated $110,886
- SQUAREPOINT OPS LLC removed 260,247 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $103,057
- GSA CAPITAL PARTNERS LLP removed 233,156 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $92,329
- ACADIAN ASSET MANAGEMENT LLC removed 197,558 shares (-11.7%) from their portfolio in Q2 2025, for an estimated $78,232
- TWO SIGMA ADVISERS, LP removed 174,800 shares (-92.5%) from their portfolio in Q2 2025, for an estimated $69,220
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics using its proprietary CAB platform for the treatment of solid tumors, today announced that clinical data for its investigational AXL-targeting antibody-drug conjugate (ADC), mecbotamab vedotin (BA3011), will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting to be held at National Harbor, MD from November 5-9, 2025.
The presentation, titled “Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC” , will be delivered by Dr. Mihaela Druta of Moffitt Cancer Center on Friday, November 7, 2025 . The abstract (#523) will be featured in the poster session, with presentation time to be announced.
A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentation has concluded.
About BioAtla ® , Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. To learn more about BioAtla, Inc., visit www.bioatla.com .
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
[email protected]
858.356.8945
External Contact:
Joyce Allaire
LifeSci Advisors, LLC
[email protected]
